Patent intelligence · US
US 12084504
Anti-MET antibodies and uses thereof
Anti-MET antibodies and uses thereof
Patent details — US 12084504
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 10, 2024
- Expiration
- Sep 5, 2044
- Applicant
- AGOMAB THERAPEUTICS
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61P, A61P1/00
Quick answer
US 12084504 (Anti-MET antibodies and uses thereof) is held by AGOMAB THERAPEUTICS. Status: granted. Granted Sep 10, 2024. Expires Sep 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AGOMAB THERAPEUTICS
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K2039/505, A61P, A61P1/00, A61P1/04, A61P1/16
More from AGOMAB THERAPEUTICS
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12084504?
US 12084504 (Anti-MET antibodies and uses thereof) is held by AGOMAB THERAPEUTICS. Status: granted. Granted Sep 10, 2024. Expires Sep 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12084504?
AGOMAB THERAPEUTICS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12084504 expire?
Our index shows an expiration date of Sep 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.